Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at SOT 63rd Annual Meeting and ToxExpo

2024-02-04
|
Page View:

1.png

SOT 63rd Annual Meeting and ToxExpo

More Science, More Networking, More Everything in 2024

SOT is returning to Salt Lake City for the first time in more than a decade for its 63rd Annual Meeting and ToxExpo. The 2024 meeting will feature five days of Featured and Scientific Sessions, poster presentations, and social events, as well as the popular three-day ToxExpo.

Medicilon is excited to attend and exhibit at the conference. Dr. Haizhou Zhang, president of preclinical R&D unit at Medicilon, will be available at the booth. Dr. Zhang holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.

We are getting ready. Are you?
Date: March 10-14, 2024
Location: Salt Palace Convention Center, Salt Lake City, Utah

Medicilon Booth: 1408

Medicilon Toxicology Studies Services

Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones.

By the end of 2023, we have served more than 2000 clients globally with more than 300 INDs approved in China and more than 80 INDs approved overseas using toxicology data generated by Medicilon.

Meet with Medicilon
Subject丨SOT 63rd Annual Meeting and ToxExpo

Share:
Return
Relevant newsRelevant news